Last10K.com

Amyris, Inc. (AMRS) SEC Filing 10-Q Quarterly report for the period ending Tuesday, March 31, 2020

SEC Filings

AMRS Quarterly Reports

Amyris, Inc.

CIK: 1365916 Ticker: AMRS

image01.jpg      
FOR IMMEDIATE RELEASE

Investor Contact       
Peter DeNardo  
Amyris, Inc.
+1 (510) 597-5592  
denardo@amryis.com

AMYRIS, INC. REPORTS
FIRST QUARTER 2020 RESULTS

Sales Revenue Doubled Versus Prior Year Quarter

Strong Gross Margin And Earnings Growth From Improved Sales Mix And Lower Costs

Significantly Improved Balance Sheet From Reduced Debt


EMERYVILLE, CA – May 8, 2020
– Amyris, Inc. (Nasdaq: AMRS), a leading synthetic biotechnology company in Clean Health and Beauty markets through its consumer brands and a top supplier of sustainable and natural ingredients, today announced financial results for its first quarter ended March 31, 2020.

Keeping our people, partners and communities safe and healthy while benefiting from strong product demand has been our number one priority during these unprecedented times with COVID-19.

Management Comments
“COVID-19 has dominated all of our lives with a significant impact both from a health and economic perspective. Keeping our people, our partners and our communities safe and healthy while delivering on very strong product demand from consumers has been our number one priority. This meant that we had to adjust our ways of working across our supply chain, innovation center and offices. Our people have been amazing, and we have continued to deliver on our commitments to our customers,” said John Melo, President and Chief Executive Officer. “We play a critical role in helping those who have been impacted by the pandemic. This includes rapidly launching a new hand sanitizer of which we have donated over 20,000 units to frontline healthcare workers. Also, we supply key ingredients for household cleaning and personal care products and are exploring how our science can be further utilized to fight the virus.”

Continued Melo, “We are pleased with our first quarter results for what is typically our lowest sales quarter of the year due to seasonality. We have seen limited impact to our business performance from COVID-19. During the month of April we delivered our best single month of consumer product sales. We are experiencing significant demand for our ingredients into cleaning products and personal care products. We are encouraged by the growth in our top and bottom-line performance and see continued opportunity with our strong portfolio of branded consumer products and functional ingredients. Our focus on higher margin product sales and reducing unit costs by adapting our supply chain are


The following information was filed by Amyris, Inc. (AMRS) on Friday, May 8, 2020 as an 8K 2.02 statement, which is an earnings press release pertaining to results of operations and financial condition. It may be helpful to assess the quality of management by comparing the information in the press release to the information in the accompanying 10-Q Quarterly Report statement of earnings and operation as management may choose to highlight particular information in the press release.

View differences made from one quarter to another to evaluate Amyris, Inc.'s financial trajectory

Compare SEC Filings Year-over-Year (YoY) and Quarter-over-Quarter (QoQ)
Sample 10-K Year-over-Year (YoY) Comparison

Compare this 10-Q Quarterly Report to its predecessor by reading our highlights to see what text and tables were  removed  ,   added    and   changed   by Amyris, Inc..

Continue

Assess how Amyris, Inc.'s management team is paid from their Annual Proxy

Definitive Proxy Statement (Form DEF 14A)
Screenshot example of actual Proxy Statement

Amyris, Inc.'s Definitive Proxy Statement (Form DEF 14A) filed after their 2020 10-K Annual Report includes:

  • Voting Procedures
  • Board Members
  • Executive Team
  • Salaries, Bonuses, Perks
  • Peers / Competitors

Continue

SEC Filing Tools

Rating

Learn More
Bullish Bearish Neutral
Filter Sentiment:
All
Positive
Negative
Filter Category:
All
Financial
Revenue
Other
Filter Subcategory:
All
Debt
Expense
Product
Cash Flow
Shares
Earnings
Geography
Other
Inside Amyris, Inc.'s 10-Q Quarterly Report:

Financial Statements, Disclosures and Schedules

Inside this 10-Q Quarterly Report

Cover Page
Condensed Consolidated Balance Sheets
Condensed Consolidated Balance Sheets (Parentheticals)
Condensed Consolidated Statements Of Cash Flows
Condensed Consolidated Statements Of Comprehensive Loss
Condensed Consolidated Statements Of Operations
Condensed Consolidated Statements Of Operations (Parentheticals)
Consolidated Statements Of Stockholders' Deficit And Mezzanine Equity Consolidated Statements Of Stockholders' Deficit And Mezzanine Equity
Balance Sheet Details
Balance Sheet Details (Tables)
Balance Sheet Details - Accrued And Other Current Liabilities (Details)
Balance Sheet Details - Additional Information (Details)
Balance Sheet Details - Allowance For Doubtful Accounts (Details)
Balance Sheet Details - Deferred Cost Of Products Sold - Related Party (Details)
Balance Sheet Details - Depreciation And Amortization (Details)
Balance Sheet Details - Inventory, Current (Details)
Balance Sheet Details - Maturities Of Financing And Operating Leases (Details)
Balance Sheet Details - Other Assets (Details)
Balance Sheet Details - Other Noncurrent Liabilities (Details)
Balance Sheet Details - Prepaid Expenses And Other Current Assets (Details)
Balance Sheet Details - Property, Plant And Equipment (Details)
Balance Sheet Details Balance Sheet Details - Right-Of-Use Assets And Related Lease Liabilities (Details)
Basis Of Presentation And Summary Of Significant Accounting Policies
Basis Of Presentation And Summary Of Significant Accounting Policies (Details)
Basis Of Presentation And Summary Of Significant Accounting Policies (Policies)
Commitments And Contingencies
Debt
Debt (Tables)
Debt - 2014 Rule 144A Note Exchange And Extension - Total, Related Party (Details)
Debt - Debt Components (Details)
Debt - Debt Equitization - Foris Related Party (Details)
Debt - Exchange Of Senior Convertible Notes Due 2022 (Details)
Debt - Future Minimum Payments (Details)
Debt - Ginkgo Waiver Agreement (Details)
Debt - Nikko Secured Loan Agreement Amendment (Details)
Debt - Schottenfeld Forbearance Agreement (Details)
Fair Value Measurement
Fair Value Measurement (Tables)
Fair Value Measurement - Additional Information (Details)
Fair Value Measurement - Convertible Debt (Details)
Fair Value Measurement - Fair Value, Assets, And Liabilities Measured On Recurring Basis (Details)
Fair Value Measurement - Market-Based Assumption And Estimates For Compound Embedded Derivative Liabilities Valuation (Details)
Fair Value Measurement - Reconciliation For Compound Embedded Derivative Liability (Details)
Loss Per Share
Loss Per Share (Tables)
Loss Per Share - Antidilutive Securities Excluded From Computation Of Earnings Per Share (Details)
Loss Per Share - Calculation Of Basic And Diluted Net Loss Per Share Of Common Stock (Details)
Mezzanine Equity
Mezzanine Equity (Details Textual)
Related Party Transactions
Related Party Transactions (Tables)
Related Party Transactions - Related Party Accounts Receivable (Details)
Related Party Transactions - Related Party Debt (Details)
Revenue Recognition And Contact Assets And Liabilities - Narrative (Details)
Revenue Recognition And Contract Assets And Liabilities
Revenue Recognition And Contract Assets And Liabilities (Tables)
Revenue Recognition And Contract Assets And Liabilities - Contract Balances (Details)
Revenue Recognition And Contract Assets And Liabilities - Disaggregation Of Revenue (Details)
Revenue Recognition And Contract Assets And Liabilities - Remaining Performance Obligations (Details)
Revenue Recognition And Contract Assets And Liabilities - Revenue In Connection With Significant Revenue Agreement (Details)
Stock-Based Compensation
Stock-Based Compensation (Details Textual)
Stock-Based Compensation (Tables)
Stock-Based Compensation - Employee Service Share-Based Compensation, Allocation Of Recognized Period Costs (Details)
Stock-Based Compensation - Share-Based Compensation, Stock Options And Stock Appreciation Rights Award Activity (Details)
Stock-Based Compensation - Temporal Display Of Share-Based Compensation, Restricted Stock And Restricted Stock Units Activity (Details)
Stockholders' Deficit
Stockholders' Deficit (Tables)
Stockholders' Deficit - Foris Warrant Exercises For Cash (Details)
Stockholders' Deficit - January 2020 Private Placement (Details)
Stockholders' Deficit - January 2020 Warrant Amendments And Exercises, Foris Debt Equitization And Private Placement (Details)
Stockholders' Deficit - Warrant Activity (Details)
Stockholders' Deficit - Warrant Amendments And Exercise By Certain Holders (Details)
Stockholders' Deficit - Warrant Amendments And Exercises, Common Stock Purchase And Debt Equitization By Foris- Related Party (Details)
Subsequent Events
Subsequent Events (Details)
Ticker: AMRS
CIK: 1365916
Form Type: 10-Q Quarterly Report
Accession Number: 0001365916-20-000074
Submitted to the SEC: Mon May 11 2020 5:19:54 PM EST
Accepted by the SEC: Mon May 11 2020
Period: Tuesday, March 31, 2020
Industry: Industrial Organic Chemicals

External Resources:
Stock Quote
Social Media

Bookmark the Permalink:
https://last10k.com/sec-filings/amrs/0001365916-20-000074.htm